MEREO BIOPHARMA GROUP PLC MREO

* Summed across managers. Shares that two managers' reports both contain – a subsidiary's holdings that its parent's report includes too, or a sub-adviser's in its client's – are counted once. Holder counts are more reliable. Implied quarter-end price ≈ $0.32. Options: 5 managers hold calls ($286.6k notional), 4 hold puts ($31.0k).

Trends to Q2 2026

Options at notional value: the value of the shares the contracts control, as filers report them, not what the options cost. Not included in the holders, shares or buying above.

Major shareholders (over 5%)

Anyone who owns more than 5% of a class of the company's shares has to say so: on Schedule 13D if they may try to influence or control the company, on 13G if they're a passive investor, and update it as the stake changes. Each holder's latest filing, from 19 Dec 2024 on; percentages are of the share class, as the holder worked them out.

Fell to 5% or below in the last year: BANK OF AMERICA CORP /DE/ (3.4%, 2026-10-28), EcoR1 Capital, LLC (6.0%, 2026-08-14), JANUS HENDERSON GROUP PLC (0.0%, 2026-02-17), Northpond Ventures, LP (0.0%, 2026-02-17), Frazier Life Sciences Public Fund, L.P. (0.0%, 2026-02-13), MANGROVE PARTNERS IM, LLC (4.9%, 2025-11-14)

Insider purchases and sales since 1 Apr 2026

Shares bought or sold by the company's own officers, directors and 10% owners, in the open market or privately, as they reported to the SEC on Form 4 (due within two business days of the trade). Grants, option exercises, shares withheld for tax and gifts aren't included.

None reported since 1 Apr 2026.

Holders, Q2 2026